The U.S. Food and Drug Administration (FDA) has approved British pharmaceutical company GSK\u2019s (GSK.L) combination vaccine, Penmenvy, for use in individuals aged 10 to 25, the company announced on Saturday.<\/p>\n
Meningococcal infections, caused by Neisseria meningitidis<\/em> bacteria, can result in severe and potentially fatal bloodstream infections, as well as dangerous inflammation in the brain and spinal cord.<\/p>\n Penmenvy is a pentavalent vaccine that merges the protective components of GSK\u2019s two existing vaccines, Bexsero and Menveo, to offer immunity against the five most common meningococcal strains (A, B, C, W, and Y).<\/p>\n According to the U.S. Centers for Disease Control and Prevention (CDC), 438 confirmed and probable cases of meningococcal disease were reported in the U.S. in 2023. The agency also noted that cases have been rising sharply since 2021, surpassing pre-pandemic levels.<\/p>\n Medical experts believe the new combination vaccine could improve vaccination rates by reducing the number of injections required.<\/p>\n “Having a single shot that offers broad protection simplifies the process, making it easier to increase immunization coverage,” said Dr. Patty Sabey, a pediatrician at Stanford Medicine Children’s Health. She also emphasized that timely vaccination could help reduce the risk of serious complications such as brain damage and hearing loss.<\/p>\n The FDA’s approval was based on results from a late-stage clinical trial involving approximately 3,650 participants aged 10 to 25. The study confirmed that Penmenvy was as effective as Bexsero and Menveo in preventing meningococcal infections caused by the five targeted strains.<\/p>\n The vaccine was well tolerated, with a safety profile consistent with the individual vaccines, GSK reported.<\/p>\n Bexsero, which protects against meningococcal serogroup B, and Menveo, approved in over 60 countries for serogroups A, C, W, and Y, have been widely used for meningococcal disease prevention.<\/p>\n With this approval, GSK\u2019s Penmenvy joins Pfizer\u2019s Penbraya, which became the first pentavalent meningococcal vaccine approved by the FDA in 2023. However, Pfizer withdrew its marketing authorization for Penbraya in Europe earlier this year, citing commercial reasons.<\/p>\n Penmenvy\u2019s approval marks a significant step in streamlining meningococcal disease prevention, offering broad protection in a single dose\u2014a move that could enhance accessibility and uptake among at-risk populations.<\/p>\n","protected":false},"excerpt":{"rendered":" The U.S. Food and Drug Administration (FDA) has approved British pharmaceutical company GSK\u2019s (GSK.L) combination vaccine, Penmenvy, for use in individuals aged 10 to 25, the company announced on Saturday.…<\/p>\n","protected":false},"author":1,"featured_media":6053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[73,78],"tags":[],"class_list":["post-6048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-global","category-regulatory"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/regtechafrica.com\/healthcare\/wp-content\/uploads\/2025\/02\/gsk-shutterstock_2262780591-770x433-1.jpg?fit=770%2C433&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/comments?post=6048"}],"version-history":[{"count":1,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6048\/revisions"}],"predecessor-version":[{"id":6054,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/posts\/6048\/revisions\/6054"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media\/6053"}],"wp:attachment":[{"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/media?parent=6048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/categories?post=6048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regtechafrica.com\/healthcare\/wp-json\/wp\/v2\/tags?post=6048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}A Simplified Vaccination Approach<\/h3>\n
Clinical Data and Safety Profile<\/h3>\n
Expanding the Market for Meningococcal Vaccines<\/h3>\n